Skip to main content
. 2019 Feb 4;9:1282. doi: 10.1038/s41598-018-38004-5

Figure 3.

Figure 3

Effect of cisplatin and metformin on clonogenic survival and radiosensitization of human NSCLC cells. (A) Cisplatin reduced clonogenic survival of NSCLC cells. A549 and H460 cells were treated with increasing concentrations of cisplatin (0–5 µM) for 4 h and clonogenic survival was determined. Average results of 2–3 independent experiments are shown. (B) Metformin reduced clonogenic survival of NSCLC cells. A549 and H460 cells were treated with increasing concentrations of metformin (0–2 mM) for 48 h and clonogenic survival was determined. Average results of 2–3 independent experiments are shown. (C,D) Survival curves for cells treated with cisplatin (red dots) versus untreated cells (black dots) after irradiation. Both cell lines were pre-treated with cisplatin (CP, 1 µM) for 4 h and subsequently exposed to radiation doses of 0–6 Gy. Clonogenic survival was determined and data at doses between 2 Gy and 6 Gy were fitted to a general linear model. Average results of 5–6 independent experiments are shown. (E,F) Metformin enhances the radiosensitizing effects of cisplatin in NSCLC cells. A549 and H460 cells were first treated with 1 mM and 2 mM metformin (MET), respectively, for 48 h followed by cisplatin (CP) treatment (1 µM) for 4 h. Cells were subsequently subjected to 0–6 Gy of radiation. Clonogenic survival was determined and data of 5–6 independent experiments are shown.